Despite high vaccine coverage and effectiveness, the incidence of symptomatic infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been increasing in Israel. Whether the increasing incidence of infection is due to waning immunity after the receipt of two doses of the BNT162b2 vaccine is unclear.

Matéria original

Anterior

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel

Próxima

A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration